We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Treatment with diabetes drug canagliflozin lowers the PromarkerD risk score for developing diabetic kidney disease in patients with type 2 diabetes, latest research suggests.
More than four in 10 patients with diabetes have diabetic kidney disease (DKD), according to a study published online June 14 in BMJ Open Diabetes Research & Care.
Amgen announced the U.S. Food and Drug Administration (FDA) has approved the expansion of the Kyprolis® (carfilzomib) U.S. prescribing information to include its use in combination with Darzalex® (daratumumab) plus dexamethasone (DKd) in two dosing ...
Precision Diabetes, LLC, an emerging leader in precision diabetes diagnostics, announced results today from two landmark diabetes studies on its predictive tests for kidney and cardiovascular complications of diabetes.